logo
  Join        Login             Stock Quote

Mylan (MYL) Launches Generic Version Of Osteoporosis Treatment In UK, Italy

 May 24, 2012 02:43 PM
 


(By Balachander) Mylan Inc. (NASDAQ:MYL), one of the world's largest generic drugmakers, announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy.

The Canonsburg, Pennsylvania-based company said the launch of generic Ibandronic Acid tablets expands its strong portfolio of more than 350 products in the UK and 340 products in Italy.

Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.

Ibandronic Acid Film Coated Tablets POM had sales of about 8.5 million euros ($10.65 million) in the UK and sales of about 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.

Last week, the company announced the launch of generic version of Sanofi-Aventis' (NYSE: SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. unit has received final clearance from the U.S. health regulators for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Earlier this month, Mylan announced the launch of the generic version of Pfizer's (NYSE: PFE) Lipitor, the top-selling cholesterol controlling drug, in France, Belgium, the UK, the Netherlands and Ireland.

MYL shares, which have been trading in the 52-week range of $15.49 to $25.00, added 0.67 percent to trade at $21.04 on Thursday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.